HSPA4

Across TCGA pan-cancer cohorts, HSPA4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HSPA4 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher HSPA4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HSPA4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, HNSC, and UCEC are the cancer types where HSPA4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.137	0.700	<.001	48	view →
HNSC	OS	Median	III,IV	0.201	0.729	<.001	37	view →
UCEC	DFS	Median	II,III,IV	0.945	0.426	.004	34	view →
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HSPA4–SCLC (OS)

Open the SCLC breakdown →